Literature DB >> 22190392

Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.

Mariana Baz1, Mukesh Samant, Hakima Zekki, Pascale Tribout-Jover, Martin Plante, Anne-Marie Lanteigne, Marie-Eve Hamelin, Corey Mallett, Barbara Papadopoulou, Guy Boivin.   

Abstract

Influenza A/H3N2 viruses have caused the most severe epidemics since 1968 despite current immunization programs with inactivated vaccines. We undertook a side-by-side preclinical evaluation of different adjuvants (Alum, AS03, and Protollin) and routes of administration (intramuscular [i.m.] and intranasal [i.n.]) for assessing their effect on the immunogenicity and cross-reactivity of inactivated split vaccines (A/H3N2/New York/55/2004). Humoral and T cell-mediated immune responses against the homologous virus and a heterologous drifted strain (A/H3N2/Wisconsin/67/2005) were measured in BALB/c mice at 2, 6, and 19 weeks postboost. The AS03- and Alum-adjuvanted i.m. vaccines induced at least an 8-fold increase over the nonadjuvanted vaccine in functional antibody titers against both the homotypic and heterotypic strains and low IgG2a and high IgG1 levels, suggesting a mixed Th1/Th2 response with a Th2 trend. The Protollin-adjuvanted i.n. vaccine induced the lowest IgG1/IgG2a ratio, which is indicative of a mixed Th1/Th2-type profile with a Th1 trend. This adjuvanted vaccine was the only vaccine to stimulate a mucosal IgA response. Whatever the timing after the boost, both hemagglutination inhibition (HAI) and microneutralization (MN) titers were higher with the AS03-adjuvanted i.m. vaccine than with the protollin-adjuvanted i.n. vaccine. Finally, the Alum-adjuvanted i.m. vaccine and the lower-dose Protollin-adjuvanted i.n. vaccine elicited significantly higher CD4(+) Th1 and Th2 responses and more gamma interferon (IFN-γ)-producing CD8(+) T cells than the nonadjuvanted vaccine. Our data indicate that the adjuvanted vaccines tested in this study can elicit stronger, more persistent, and broader immune responses against A/H3N2 strains than nonadjuvanted inactivated influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22190392      PMCID: PMC3272927          DOI: 10.1128/CVI.05441-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  47 in total

1.  A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

Authors:  Taff Jones; Francine Allard; Sonya L Cyr; Steven P Tran; Martin Plante; Joelle Gauthier; Nathalie Bellerose; George H Lowell; David S Burt
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

2.  Surveillance for influenza--United States, 1997-98, 1998-99, and 1999-00 seasons.

Authors:  T Lynnette Brammer; Erin L Murray; Keiji Fukuda; Henrietta E Hall; Alexander Klimov; Nancy J Cox
Journal:  MMWR Surveill Summ       Date:  2002-10-25

3.  Brain aluminum distribution in Alzheimer's disease and experimental neurofibrillary degeneration.

Authors:  D R Crapper; S S Krishnan; A J Dalton
Journal:  Science       Date:  1973-05-04       Impact factor: 47.728

4.  Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation.

Authors:  J W Mannhalter; H O Neychev; G J Zlabinger; R Ahmad; M M Eibl
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

Review 5.  Immunity to influenza in man.

Authors:  R B Couch; J A Kasel
Journal:  Annu Rev Microbiol       Date:  1983       Impact factor: 15.500

6.  Genetic relatedness between the new 1977 epidemic strains (H1N1) of influenza and human influenza strains isolated between 1947 and 1957 (H1N1).

Authors:  C Scholtissek; V von Hoyningen; R Rott
Journal:  Virology       Date:  1978-09       Impact factor: 3.616

7.  Side effects during immunotherapy with purified grass pollen extracts.

Authors:  O Osterballe
Journal:  Allergy       Date:  1982-11       Impact factor: 13.146

8.  Protollin: a novel adjuvant for intranasal vaccines.

Authors:  Taff Jones; Sonya Cyr; Francine Allard; Nathalie Bellerose; George H Lowell; David S Burt
Journal:  Vaccine       Date:  2004-09-09       Impact factor: 3.641

Review 9.  Aluminium compounds for use in vaccines.

Authors:  Erik B Lindblad
Journal:  Immunol Cell Biol       Date:  2004-10       Impact factor: 5.126

Review 10.  Adjuvants--a balance between toxicity and adjuvanticity.

Authors:  R K Gupta; E H Relyveld; E B Lindblad; B Bizzini; S Ben-Efraim; C K Gupta
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

View more
  23 in total

1.  Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

Authors:  Heng Liu; Jacqueline de Vries-Idema; Wouter Ter Veer; Jan Wilschut; Anke Huckriede
Journal:  Med Microbiol Immunol       Date:  2013-09-24       Impact factor: 3.402

2.  Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice.

Authors:  Karen K Yam; Angela Brewer; Virginie Bleau; Édith Beaulieu; Corey P Mallett; Brian J Ward
Journal:  Hum Vaccin Immunother       Date:  2016-10-21       Impact factor: 3.452

3.  Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.

Authors:  Sonali Kochhar
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

4.  A method to identify protein antigens of Dermanyssus gallinae for the protection of birds from poultry mites.

Authors:  Gustavo R Makert; Susanne Vorbrüggen; Maria-Elisabeth Krautwald-Junghanns; Matthias Voss; Kai Sohn; Tilo Buschmann; Sebastian Ulbert
Journal:  Parasitol Res       Date:  2016-03-30       Impact factor: 2.289

5.  Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance.

Authors:  Danuta M Skowronski; Marie-Eve Hamelin; Naveed Z Janjua; Gaston De Serres; Jennifer L Gardy; Chantal Rhéaume; Xavier Bouhy; Guy Boivin
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

6.  Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.

Authors:  Eun-Do Kim; Soo Jung Han; Young-Ho Byun; Sang Chul Yoon; Kyoung Sub Choi; Baik Lin Seong; Kyoung Yul Seo
Journal:  PLoS One       Date:  2015-09-10       Impact factor: 3.240

7.  Microneedle Vaccination Elicits Superior Protection and Antibody Response over Intranasal Vaccination against Swine-Origin Influenza A (H1N1) in Mice.

Authors:  Ju-Hyung Shin; Jae-Keun Park; Dong-Hun Lee; Fu-Shi Quan; Chang-Seon Song; Yeu-Chun Kim
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

8.  AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice.

Authors:  Karen K Yam; Jyotsana Gupta; Kaitlin Winter; Elizabeth Allen; Angela Brewer; Édith Beaulieu; Corey P Mallett; David S Burt; Brian J Ward
Journal:  Front Immunol       Date:  2015-04-29       Impact factor: 7.561

9.  Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.

Authors:  Joseph R Francica; Barbara J Flynn; Kathryn E Foulds; Amy T Noe; Anne P Werner; Ian N Moore; Matthew Gagne; Timothy S Johnston; Courtney Tucker; Rachel L Davis; Britta Flach; Sarah O'Connell; Shayne F Andrew; Evan Lamb; Dillon R Flebbe; Saule T Nurmukhambetova; Mitzi M Donaldson; John-Paul M Todd; Alex Lee Zhu; Caroline Atyeo; Stephanie Fischinger; Matthew J Gorman; Sally Shin; Venkata Viswanadh Edara; Katharine Floyd; Lilin Lai; Seyhan Boyoglu-Barnum; Renee Van De Wetering; Alida Tylor; Elizabeth McCarthy; Valerie Lecouturier; Sophie Ruiz; Catherine Berry; Timothy Tibbitts; Hanne Andersen; Anthony Cook; Alan Dodson; Laurent Pessaint; Alex Van Ry; Marguerite Koutsoukos; Cindy Gutzeit; I-Ting Teng; Tongqing Zhou; Dapeng Li; Barton F Haynes; Peter D Kwong; Adrian McDermott; Mark G Lewis; Tong Ming Fu; Roman Chicz; Robbert van der Most; Kizzmekia S Corbett; Mehul S Suthar; Galit Alter; Mario Roederer; Nancy J Sullivan; Daniel C Douek; Barney S Graham; Danilo Casimiro; Robert A Seder
Journal:  Sci Transl Med       Date:  2021-07-27       Impact factor: 19.319

Review 10.  Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Authors:  Elke S Bergmann-Leitner; Wolfgang W Leitner
Journal:  Vaccines (Basel)       Date:  2014-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.